Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
Open Access
- 1 June 1999
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 42 (6) , 1246-1254
- https://doi.org/10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS StudyJournal of Bone and Mineral Research, 1997
- Bisphosphonate Effects and the Bone Remodeling TransientJournal of Bone and Mineral Research, 1997
- Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of OsteoporosisJournal of Bone and Mineral Research, 1997
- Fractures Among the Elderly: An Old ProblemJournal of Bone and Mineral Research, 1997
- Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up StudyBone, 1996
- Determinants of vertebral fracture prevalence among native Japanese women and women of japanese descent living in HawaiiBone, 1996
- Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up studyBone, 1996
- Report assessing vertebral fracturesJournal of Bone and Mineral Research, 1995
- Bone age, mineral density, and fatigue damageCalcified Tissue International, 1993